Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Cancer Vaccines01:30

Cancer Vaccines

510
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
510

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Timing of the first dressing change after CVC insertion in pediatric critically ill patients: a randomized controlled, non-inferiority trial.

Scientific reports·2026
Same author

Genome-Wide Identification, Evolutionary Analysis and Seasonal Expression Patterns of the Sox Gene Family in the Daurian Ground Squirrel (<i>Spermophilus dauricus</i>).

Veterinary sciences·2026
Same author

Gene- and subtype-dependent prognostic impact of ras pathway mutations in acute myeloid leukemia: a cohort study of 2,500 patients.

Blood cancer journal·2026
Same author

Venetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia.

Blood·2026
Same author

Factors associated with first-attempt success of peripheral arterial catheterization in a pediatric intensive care unit: a prospective observational study.

Frontiers in pediatrics·2026
Same author

Ginsenoside-Rh2 inhibits U251 glioma cell migration and invasion via the Gab2/Akt2 pathway.

Frontiers in oncology·2026

相关实验视频

Updated: Sep 12, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

797

CD7 CAR-T疗法:当前的发展,改善和困境

Linjuan Wang1,2, Shaowei Qiu1,2

  • 1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

Blood science (Baltimore, Md.)
|August 7, 2025
PubMed
概括

化学抗原受体 (CAR) 针对CD7的T细胞疗法在复发/耐药T细胞白血病中显示出前景. 全基因CAR-T细胞提供了优势,但面临着像GVHD这样的挑战,基因编辑和新型细胞来源提供了潜在的解决方案.

关键词:
在AML,AML就是AML.在CART-T中,我们可以使用CAR-T.在CD7 CD7 CD7 CD7 CD7在GVHD中,GVHD是指GVHD临床应用 临床应用杀害兄弟的方法是兄弟杀戮.r/r T-ALL/LBL 在线阅读

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

相关实验视频

Last Updated: Sep 12, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

797
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

科学领域:

  • 免疫治疗是一种免疫疗法.
  • 在瘤学瘤学.
  • 细胞疗法细胞疗法

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法彻底改变了B细胞恶性瘤的治疗方法.
  • 它在T细胞恶性瘤,特别是T细胞急性淋巴细胞白血病/淋巴细胞淋巴瘤 (T-ALL/LBL) 和急性髓性白血病 (AML) 中的应用仍然是一个重大挑战.
  • CD7已经成为T细胞恶性瘤的关键向抗原.

研究的目的:

  • 审查CD7 CAR-T产品的不同类别.
  • 讨论它们的临床应用和挑战.
  • 探索 CD7 CAR-T 治疗的潜在解决方案和未来方向.

主要方法:

  • 对CD7 CAR-T疗法的现有文献的综述.
  • 自生与异性CAR-T细胞产物的分析.
  • 检查诸如移植与宿主疾病 (GVHD),宿主与移植反应 (HVGR) 和兄弟杀戮等挑战.
  • 探索基因编辑技术 (CRISPR/Cas9,基因编辑) 和新型细胞来源 (NKT细胞,iPSCs).

主要成果:

  • 与自身的CAR-T细胞相比,全基CD7CAR-T细胞在制造成本,质量一致性,负担能力和可用性方面具有优势.
  • 包括GVHD,HVGR和兄弟杀戮在内的重大挑战阻碍了全基CD7CAR-T细胞的临床使用.
  • 为了克服这些障碍,正在研究创新的基因编辑技术和替代细胞来源.

结论:

  • CD7 CAR-T疗法具有治疗复发性/耐药性T细胞恶性瘤的显著潜力.
  • 全基因方法提供实用益处,但需要缓解与免疫相关的毒性.
  • 基因编辑和细胞采购方面的进步对于CD7 CAR-T疗法的成功临床转化至关重要.